Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease

Bibliography

• Poewe W. The natural history of Parkinson's disease. J Neurol 2006;253(Suppl 7):VII2-VII6
   PubMedGoogle Scholar
• Andlin-Sobocki P, Jonsson B, Wittchen HU, Cost of disorders of the brain in Europe. Eur J Neurol 2005;12(Suppl 1):1-27
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339:1044-53
   PubMed Web of Science ®Google Scholar
• Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003;18:19-31
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. Parkinsonism Relat Disord 1998;4:59-60
   PubMedGoogle Scholar
• Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990;40:340-5
   PubMed Web of Science ®Google Scholar
• Rascol O, Payoux P, Ory F, Limitations of current Parkinson's disease therapy. Ann Neurol 2003;53(Suppl 3):S3-12
   PubMedGoogle Scholar
• Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009;72:S1-136
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87
   PubMed Web of Science ®Google Scholar
• Stocchi F. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl 3):S68-71
   PubMedGoogle Scholar
• Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41:261-309
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Brefel-Courbon C, Senard JM, Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol 2001;24:181-3
   PubMed Web of Science ®Google Scholar
• Uitti RJ, Ahlskog JE, Maraganore DM. Does levodopa therapy delay death in Parkinson's disease? Mov Disord 1996;11:343-4
   PubMedGoogle Scholar
• Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-9
   PubMed Web of Science ®Google Scholar
• Schapira AH. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 2009;72:S44-50
   PubMed Web of Science ®Google Scholar
• Koller WC, Hutton JT, Tolosa E, Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999;53:1012-19
   PubMed Web of Science ®Google Scholar
• Schrag A. Entacapone in the treatment of Parkinson's disease. Lancet Neurol 2005;4:366-70
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Kieburtz K, Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18-27
   PubMed Web of Science ®Google Scholar
• Eggert K, Schrader C, Hahn M, Continuous jejunal levodopa infusion in patients with advanced Parkinson's disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-66
   PubMed Web of Science ®Google Scholar
• Bracco F, Battaglia A, Chouza C, The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004;18:733-46
   PubMed Web of Science ®Google Scholar
• Oertel WH, Wolters E, Sampaio C, Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2006;21:343-53
   PubMed Web of Science ®Google Scholar
• Parkinson's Disease Study Group. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009;66:563-70
   PubMedGoogle Scholar
• Rascol O, Brooks DJ, Korczyn AD, ; 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-91
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz PJ, Sesar IA, Ares PB, Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008;23:1130-6
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Head J, Schrag A, Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008;71:474-80
   PubMed Web of Science ®Google Scholar
• Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opin Pharmacother 2009;10:677-91
   PubMed Web of Science ®Google Scholar
• Pahwa R, Stacy MA, Factor SA, Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-15
   PubMed Web of Science ®Google Scholar
• Parkinson's Disease Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000;284:1931-8
   PubMedGoogle Scholar
• Mizuno Y, Yanagisawa N, Kuno S, Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Disord 2003;18:1149-56
   PubMed Web of Science ®Google Scholar
• Moller JC, Oertel WH, Koster J, Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005;20:602-10
   PubMed Web of Science ®Google Scholar
• Bennett JP Jr, Piercey MF. Pramipexole – a new dopamine agonist for the treatment of Parkinson's disease. J Neurol Sci 1999;163:25-31
   PubMed Web of Science ®Google Scholar
• Hubble JP. Pre-clinical studies of pramipexole: clinical relevance. Eur J Neurol 2000;7(Suppl 1):15-20
   PubMedGoogle Scholar
• Pogarell O, Gasser T, van Hilten JJ, Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002;72:713-20
   PubMed Web of Science ®Google Scholar
• Shannon KM, Bennett JP Jr, Friedman JH, Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-8
   PubMed Web of Science ®Google Scholar
• Clarke CE, Speller JM, Clarke JA. Pramipexole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2000:CD002261
   PubMedGoogle Scholar
• Guttman M, International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997;49:1060-5
   PubMed Web of Science ®Google Scholar
• Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006;28:1065-78
   PubMed Web of Science ®Google Scholar
• Jenner P, Konen-Bergman M, Schepers C, Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther 2009;31:2698-711
   PubMed Web of Science ®Google Scholar
• Hauser RA, Rascol O, Barone P, Pharmacokinetic profiling of pramipexole extended-release in Parkinson's disease patients: implication for dosing in PD patients with renal insufficiency. Mov Disord 2009;24(Suppl 1):S265-6
   Google Scholar
• Poewe WH, Barone P, Hauser RA, Pramipexole extended-release is effective in early Parkinson's disease [abstract]. Mov Disord 2009;24(Suppl 1):S273
   Google Scholar
• Schapira AH, Barone P, Hauser RA, Efficacy and safety of pramipexole extended-release for advanced Parkinson's disease [abstract]. Mov Disord 2009;24(Suppl 1):S277-8
   PubMedGoogle Scholar
• Rascol O, Barone P, Debieuvre C, Easy switching from immediate- to extended-release pramipexole in early Parkinson's disease at the same daily dosage [abstract]. Mov Disord 2009;24(Suppl 1):S362
   Google Scholar
• Barone P, Poewe W, Albrecht S, Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-80
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-61
   PubMed Web of Science ®Google Scholar
• Guttman M, Stewart D, Hussey D, Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56:1559-64
   PubMed Web of Science ®Google Scholar
• Schapira AH, Albrecht S, Barone P, Inmediate vs delayed-start pramipexole in early Parkinson's disease: the PROUD study. Parkinsonism Relat Disord 2009;15(Suppl 2):S81
   PubMedGoogle Scholar